Last reviewed · How we verify

Broncho-Vaxom — Competitive Intelligence Brief

Broncho-Vaxom (Broncho-Vaxom) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial lysate immunostimulant. Area: Immunology / Respiratory.

phase 3 Bacterial lysate immunostimulant Immunology / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Broncho-Vaxom (Broncho-Vaxom) — OM Pharma SA. Broncho-Vaxom is an oral immunostimulant that enhances innate and adaptive immune responses to prevent recurrent respiratory tract infections.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Broncho-Vaxom TARGET Broncho-Vaxom OM Pharma SA phase 3 Bacterial lysate immunostimulant
OM-85 BV OM-85 BV Chinese Academy of Medical Sciences marketed Bacterial lysate immunostimulant
OM-85 BV (Broncho-Vaxom) OM-85 BV (Broncho-Vaxom) Kecioren Education and Training Hospital marketed Bacterial lysate immunostimulant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial lysate immunostimulant class)

  1. Chinese Academy of Medical Sciences · 1 drug in this class
  2. Kecioren Education and Training Hospital · 1 drug in this class
  3. OM Pharma SA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Broncho-Vaxom — Competitive Intelligence Brief. https://druglandscape.com/ci/broncho-vaxom. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: